Section of Hepatobiliary-Pancreatic & Gastrointestinal Surgery

Medicine & Life Sciences

1. Pancreatic Neoplasms 100%
2. Adenocarcinoma 88%
3. Neoplasms 76%
4. Pancreatectomy 63%
5. Pancreaticoduodenectomy 61%
6. Survival 56%
7. sigma-2 receptor 35%
8. Pancreas 32%
9. Neoplasm Metastasis 30%
10. gemcitabine 29%
11. Cytoreduction Surgical Procedures 27%
12. Induced Hyperthermia 25%
13. Cholecystectomy 25%
14. Liver 25%
15. Ligands 22%
16. Surgeons 20%
17. Therapeutics 19%
18. Pancreatic Fistula 18%
19. Recurrence 18%
20. SW IV-134 18%
21. Laparoscopic Cholecystectomy 18%
22. Gallbladder Neoplasms 17%
23. Colorectal Neoplasms 16%
24. Databases 16%
25. Drug Therapy 16%
26. Guidelines 15%
27. Lymph Nodes 15%
28. T-Lymphocytes 15%
29. SV119 15%
30. Neoadjuvant Therapy 14%
31. Neuroendocrine Tumors 14%
32. Stomach 13%
33. Cholangiocarcinoma 13%
34. Macrophages 13%
35. Mortality 12%
36. Hepatectomy 12%
37. Immunity 12%
38. mesothelin 12%
39. Ovarian Neoplasms 11%
40. Caspases 11%
41. Proteins 11%
42. Cell Death 11%
43. Length of Stay 11%
44. Gallbladder 11%
45. Stomach Neoplasms 11%
46. Morbidity 11%
47. Monocytes 11%
48. Radiotherapy 11%
49. Bile Ducts 11%
50. Apoptosis 11%
51. Costs and Cost Analysis 10%
52. Peritoneal Neoplasms 10%
53. Liver Neoplasms 10%
54. Wounds and Injuries 9%
55. Gastric Bypass 9%
56. Radiofrequency Ablation 9%
57. Practice Guidelines 9%
58. Hepatocellular Carcinoma 8%
59. Vasculopathy, Retinal, With Cerebral Leukodystrophy 8%
60. CD55 Antigens 8%
61. Immunotherapy 8%
62. Multivariate Analysis 8%
63. Myeloid-Derived Suppressor Cells 8%
64. Dendritic Cells 8%
65. Portal Vein 8%
66. Erythrocytes 8%
67. 130-nm albumin-bound paclitaxel 8%
68. Jaundice 8%
69. Complement System Proteins 8%
70. Membranes 7%
71. Mitochondria 7%
72. Pancreatic Ducts 7%
73. Melanoma 7%
74. Lymph Node Ratio 7%
75. Appendiceal Neoplasms 7%
76. Oxaliplatin 7%
77. Herniorrhaphy 7%
78. Safety 6%
79. Immunization 6%
80. Patient Readmission 6%
81. Residual Neoplasm 6%
82. Disease-Free Survival 6%
83. Neck 6%
84. Granulocyte-Macrophage Colony-Stimulating Factor 6%
85. Operative Time 6%
86. Catenins 6%
87. Splenic Artery 6%
88. Postoperative Complications 6%
89. Growth 6%
90. DNA 6%
91. Protein Deficiency 6%
92. Confidence Intervals 6%
93. Klatskin Tumor 6%
94. Piperazine 6%
95. Splenic Vein 5%
96. Cell Line 5%
97. Sepsis 5%
98. Indoleamine-Pyrrole 2,3,-Dioxygenase 5%
99. Learning Curve 5%
100. Exonucleases 5%